Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a leading pharmaceutical company that specializes in the research, development, and manufacturing of heparin products and related biologics. Heparin is an essential anticoagulant widely used in medical treatments for preventing blood clots, making Hepalink pivotal in offering solutions crucial to cardiovascular and surgical care. The company primarily focuses on manufacturing and distributing heparin sodium API (Active Pharmaceutical Ingredient) and enoxaparin sodium injection—products critical for supporting modern medical practices in managing thrombosis. Shenzhen Hepalink serves a broad international market, highlighting its prominence in the global pharmaceutical supply chain. Additionally, the company is invested in developing innovative biotherapeutics and expanding into new therapeutic areas, underlining its commitment to addressing emerging global health challenges. Founded with a commitment to quality and innovation, Hepalink continues to impact both local and global healthcare sectors, contributing significantly to the availability of high-quality pharmaceutical products worldwide.